{"entity":{"id":"mmae","kind":"term","name":"MMAE","aka":["monomethyl auristatin E","vedotin payload","monomethyl auristatin E, vedotin"],"tldr":"MMAE is the tubulin-blocking payload in brentuximab, enfortumab, polatuzumab and tisotumab vedotin, four approved ADCs: it halts cell division and, being membrane permeable, leaks into neighbouring tumour cells. Nerve damage and low neutrophil counts are its signature side effects.","summary":"Monomethyl auristatin E is a synthetic analogue of dolastatin 10 that binds tubulin and halts mitosis. Released by cleavable linkers (typically valine-citrulline), it is membrane permeable, giving a strong bystander effect. It is a substrate for P-glycoprotein, which drives resistance. Peripheral neuropathy and neutropenia are class effects seen with brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin and tisotumab vedotin.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Monomethyl_auristatin_E","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Monomethyl_auristatin_E"}],"tags":[],"related":["efflux-pump","bystander-effect"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["enfortumab-vedotin","brentuximab-vedotin","tisotumab-vedotin","telisotuzumab-vedotin","disitamab-vedotin","zilovertamab-vedotin","cmg901"],"companies":[],"institutions":[],"pathways":[],"terms":["payload","tubulin-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/mmae/","neighbours":{"term":[{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/"},{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/"},{"id":"mc-vc-pabc","kind":"term","name":"mc-Val-Cit-PABC","route":"/terms/mc-vc-pabc/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/"},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/"},{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/"}],"pathway":[{"id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/"},{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/"}]}}